What does LifeStance Health do and what are its main business segments?

What were the key takeaways from LifeStance Health's earnings call?

What is the revenue and EPS growth rate for LifeStance Health year over year?

Did LifeStance Health beat or miss consensus estimates last quarter?

What were the key takeaways from LifeStance Health’s earnings call?

What is LifeStance Health's latest dividend and current dividend yield?

What guidance did LifeStance Health's management provide for the next earnings period?

What is LifeStance Health's gross profit margin?

- **Record Q3 Growth**: 17% visit growth, $40M EBITDA (11% margin), and 288 new clinicians added.
- **Productivity Boost**: 5% clinician productivity gains via AI tools and incentive programs.
- **Strategic Expansion**: Calm partnership and specialty services (neuropsych testing, TMS) driving high-margin growth.
- **Financial Strength**: Positive net income, and $204M cash balance support 2026 M&A and tech investments.
- **Risk Mitigation**: Minimal government payer exposure (5% of revenue) and focus on commercial insurance.

**【CEO Opening Remarks】**
- Highlighted record third-quarter results, including 17% organic visit growth and 16% revenue growth to $364 million.
- Emphasized clinician productivity improvements (5% YoY) and net clinician adds (288 new clinicians, 11% YoY), driving visit volumes to 2.3 million.
- Announced partnership with Calm to expand access to mental health care through seamless referrals.
- Projected mid-teens revenue growth in 2026, driven by clinician expansion and productivity gains.

**【CFO Financial Commentary】**
- Reported adjusted EBITDA of $40 million (11% margin), the highest since IPO, with full-year guidance raised to $146-$152 million.
- Center margin improved 16% YoY to $117 million, supported by operating leverage in G&A expenses (10% growth vs. 16% revenue growth).
- Positive net income of $1.1 million in Q3, with expectations for full-year positive net income in 2026.
- Free cash flow of $17 million and cash balance of $204 million, enabling strategic investments and M&A.
- 2026 outlook includes mid-teens revenue growth, driven by visit volume and low-single-digit rate improvements.

**【Q&A Highlights】**
- **Clinician Productivity & Retention**: Record productivity gains attributed to cash incentives, AI tools, and new patient engagement platforms. Retention remains stable, with regional pilot showing 87% retention.
- **AI & Tech Impact**: Early-stage AI adoption improving scheduling efficiency and patient conversions, with plans to expand automation in 2026.
- **M&A Strategy**: Pipeline of geographic expansion opportunities, with valuations deemed attractive. Organic growth remains primary driver.
- **Specialty Services Growth**: Neuropsych testing and Spravato/TMS services now contribute $50 million annually, with higher-margin potential.
- **Payer Risk Mitigation**: Minimal government payer exposure (5% of revenue) and focus on commercial insurance partnerships.
- **2026 Investments**: Accelerated business development hiring to strengthen referral networks and digital marketing efficiency.
- **Margin Expansion**: Target 15%-20% long-term margins through operational efficiency and tech-driven leverage.

LifeStance Health Group, Inc. (LFST) Q3 2025 Earnings Call Transcript

- **Record Q2 Growth**: $345M revenue (+11% YoY), $34M EBITDA (+19%), $57M free cash flow. 
- **Clinician Expansion**: +173 clinicians (7,780 total), 12% visit volume growth. 
- **Margin Expansion**: Center margin 31.4%, EBITDA margin 9.8% (vs. 8.6% prior). 
- **2025 Guidance Update**: EBITDA raised to $140-150M (10%+ margin), free cash flow >$100M. 
- **2026 Outlook**: Mid-teens revenue growth, 15-20% EBITDA margins, AI-driven efficiency.

**【CEO Summary Section】**
- **Strong Q2 Performance**: Revenue grew 11% YoY to $345 million, driven by 12% visit volume growth and 173 new clinicians (total 7,780). Adjusted EBITDA of $34 million (+19% YoY) and free cash flow of $57 million (highest on record). 
- **Productivity Initiatives**: Launched clinician cash incentive program and patient engagement platform to improve scheduling and retention. 
- **Long-Term Goals**: Target mid-teens revenue growth, 15-20% EBITDA margins, and expansion into new geographies via M&A. 

**【CFO Financial Commentary】**
- **Revenue Breakdown**: $157/visit (down 1% YoY due to one outlier payer), 11% center margin ($100 million). 
- **Cash Flow**: $57 million Q2 free cash flow, DSO improved to 34 days. Full-year guidance raised to $140-150 million EBITDA (9.8% margin). 
- **Q3 Outlook**: $345-365 million revenue, $33-39 million EBITDA. Back-half growth driven by 60% clinician adds, 40% productivity. 

**【Q&A Highlights】**
- **Q4 Ramp-Up**: 19% revenue growth expected, 90% from visit volume (60% clinicians, 40% productivity). AI tools for scheduling and documentation to enhance efficiency. 
- **M&A Strategy**: Focused on tuck-in acquisitions for geographic expansion, no impact on 2025 guidance. 
- **Medicare Rates**: Positive signals for 2026, but <5% revenue from government payers limits impact. 
- **AI Adoption**: Early-stage AI tools for revenue cycle and clinician support, aiming for operating leverage in 2026+.

LifeStance Health (LFST)-7 Aug 25-2025 Q2 Earnings call transcript

- **Historic profitability milestone**: Q1 2025 marks first positive net income ($700K) and double-digit EBITDA margin (10.4%).
- **Sustainable growth drivers**: 11% revenue growth fueled by 10% clinician expansion and 10% visit volume increase.
- **Operational efficiency**: $17M YoY improvement in free cash flow, DSO at 38 days (industry-leading).
- **Strategic shifts**: Transition to cash clinician incentives reduces long-term comp costs by $10M/year; digital tools enhance collections.
- **Resilient model**: Insured patient mix (90%) and hybrid care model position for macro stability.


**【CEO Summary Section】**
- Q1 2025 revenue reached $333 million, up 11% YoY, driven by clinician growth and visit volumes (2.1 million visits, +10% YoY). 
- Achieved first-ever positive net income of $700,000 and adjusted EBITDA of $35 million (10.4% margin), reflecting operational efficiency improvements.
- Clinician base expanded by 152 to 7,535, with new cash bonus program replacing stock incentives to align with quality and productivity goals.
- Introduced digital patient check-in tool, reducing DSO to 38 days and enhancing collections.
- 71% of visits virtual, with reimbursement parity between in-person and telehealth.

**【CFO Financial Commentary】**
- GAAP net income: $700,000 (vs. -$2.3M prior year). Non-GAAP adjusted EBITDA: $35M (+25% YoY). 
- Free cash flow improved by $17M YoY to -$10M, with $134M cash on hand.
- 2025 guidance: $1.4B-$1.44B revenue, $440M-$464M center margin, $130M-$150M EBITDA.
- Q2 2025 outlook: $332M-$352M revenue, $100M-$114M center margin, $28M-$34M EBITDA.
- Stock-based comp expected to decline $10M annually starting 2026 due to clinician incentive shift.

**【Q&A Key Themes】**
- **Clinician retention**: Stable turnover despite market competition, with new cash incentives and calendar filling focus.
- **Rate dynamics**: Q2 TRPV down due to single payer rate cut, but back-half rate increases and specialty growth expected to offset.
- **EHR rollout**: 3-5 year vision for modern platform to enhance clinician/patient experience, cost details TBD.
- **M&A strategy**: Disciplined, value-accretive tuck-ins and capability acquisitions, no 2025 guidance impact.
- **Recession resilience**: Insured model mitigates demand risk; potential shift from cash pay to insurance in downturns.


LifeStance Health Group, Inc. (LFST) Q1 2025 Earnings Call Transcript

- **Record 2024 Performance**: $1.25 billion revenue (+19%), $120 million EBITDA (+103%), and 9.6% margin.
- **Leadership Transition**: Dave Bourdon as CEO, Ryan McGroarty as CFO, Ken Burdick as Executive Chairman.
- **2025 Outlook**: $1.4-1.44 billion revenue, $130-150 million EBITDA, and positive free cash flow.
- **Operational Strength**: 8 million visits, 85 NPS, and 4.6/5 reviews. Digital tools driving efficiency.
- **M&A & Growth**: 25-30 de novos in 2025; 2026+ margin expansion to 15-20%.

**【CEO Opening Remarks】**
- **2024 Financial Highlights**: Revenue of $1.25 billion (+19% YoY), adjusted EBITDA of $120 million (+103% YoY), and first double-digit EBITDA margin (9.6%).
- **Leadership Transition**: Dave Bourdon appointed CEO effective March 3; Ken Burdick becomes Executive Chairman. New CFO Ryan McGroarty joins on March 17.
- **Operational Wins**: 8 million patient visits, NPS score of 85, and 4.6/5 Google reviews. Biweekly clinician payroll and digital check-in tool rollout.
- **2025 Outlook**: Organic growth-focused with $1.4-1.44 billion revenue, $130-150 million EBITDA, and positive free cash flow.

**【CFO Financial Breakdown】**
- **Q4 2024 Results**: $325 million revenue (+16% YoY), 2 million visits (+14% YoY), $160 revenue per visit. Center margin $109 million (+31% YoY), EBITDA $33 million (10.1% margin).
- **Liquidity**: $86 million annual free cash flow, $155 million cash, and net leverage 1.1x. Debt refinanced with 2.25% spread, saving $4 million/year.
- **2025 Guidance**: $1.4-1.44 billion revenue, $440-464 million center margin, $130-150 million EBITDA. Q1 2025: $320-340 million revenue, $27-33 million EBITDA.

**【Q&A Key Takeaways】**
- **Margins & Clinicians**: 2025 EBITDA flat due to rate pressure; 2026+ margin expansion to 15-20%. Clinician growth 12% YoY, retention stable despite competitive market.
- **M&A Strategy**: Disciplined, capability-focused acquisitions; 2025 de novo openings (25-30) driven by lease renewals, not macro trends.
- **Cost Dynamics**: 2025 cost per visit up due to clinician comp; G&A flat at $77-78 million/Q with payroll tax headwinds in Q1.

LFST

LFST fundamentals

Earnings Call

You can ask Aime